Objective To investigate the clinical effects and the quality of life of flupentixol-melitracen or paroxetine hydrochloride in treatment of the breast cancer patients with anxiety and depression after chemotherapy.Methods 135 breast cancer patients with anxiety and depression after chemotherapy were selected from November 2012 to January 2014 in the hospital.They were randomly divided into the treatment group ( n=68 ) and control group ( n =67 ).The control group were treated by paroxetine hydrochloride treatment, and the treatment group were treated by flupentixol-melitracen.The anxiety, depression and its impact on quality of life of patients were observed between two groups.Results After treatment, the HAMD score and HAMA score decreased significantly in two groups (P<0.05), HAMD score and HAMA score in treatment group after treatment significantly decreased compared with control group (P<0.05).After treatment, the WHOQOL-BREF score of mental health status scale of subjective feeling, the physiological domain, domain score levels in treatment group significantly increased (P<0.05), however, the quality of life of subjective feeling, social relationship and environment domains showed no significant difference.Compared with pre-treatment, only the health status of subjective feeling levels in control group post-treatment significantly increased (P<0.05).The mental health status scale of subjective feeling, the physiological domain, domain score levels in treatment group significantly decreased compared with control group ( P<0.05 ).The adverse reactions of treatment group were 5 cases (7.35%), which was significantly lower than 24 cases (35.82%) of control group(χ2 =16.22,P <0.05).Conclusion Flupentixol-melitracen combined with paroxetine hydrochloride has an obvious clinical effect in treatment of anxiety and depression in patients with breast cancer after chemotherapy.It could effectively control their anxiety and depression, and improve the quality of life of patients.It is worthy of clinical popularization and application.

Objective:To understand the characteristics of scientific research cooperation network, research hotspots, evolution paths and development trends of advance care planning (ACP) , so as to provide reference for follow-up related research.Methods:With the theme of "advance care planning", the retrieval results based on Web of Science core collection database were respectively imported into VOS viewer and CiteSpace for visual analysis, and the retrieval time was from database construction to February 3, 2021.Results:A total of 2 456 articles meet the selection criteria. The annual publications were all less than 50 from 1993 to 2009, which showed a rapid upward trend from 2010 to now. The distribution trend of citation frequency was basically the same as that of publications. Most of the authors and institutions are European and American. Chan Helen Yue-lai of the Chinese University of Hong Kong ranked first in China and 19th in the world in terms of publicationsand Chinese scholars' research in this field is still in its infancy. Research hotspots included ACP alternative decision-making skills training, and the research frontiers and evolutionary paths included ACP, severe mental illness, alternative decision-making, life planning, end-stage renal disease, doctor's orders, ACP model, advanced dementia, chronic heart failure, etc.Conclusions:Since 2010, the number of articles published in this field and the frequency of citations have shown a rapid upward trend. The United States, Belgium, Canada and other countries have developed well in this field and Scholars of China have a wide space for development in this field. The advanced research experience reported in the foreign ACP literature can be used for reference to deepen and speed up the clinical practice research in the field of ACP in China.